Stoke Therapeutics (STOK) Accumulated Expenses (2018 - 2026)

Stoke Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $23.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 1.78% year-over-year to $23.9 million; the TTM figure through Mar 2026 stood at $23.9 million (down 1.78% YoY), while the FY2025 annual figure was $14.0 million, down 24.73% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $23.9 million, up from $14.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $30.1 million in Q3 2025, with the low at $1.7 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $13.8 million (2023), against an average of $14.0 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses slumped 88.0% in 2024, then jumped 1372.17% in 2025.
• Stoke Therapeutics' Accumulated Expenses stood at $5.8 million in 2022, then soared by 140.09% to $13.8 million in 2023, then surged by 34.4% to $18.6 million in 2024, then retreated by 24.73% to $14.0 million in 2025, then surged by 71.03% to $23.9 million in 2026.
• Business Quant data shows STOK's Accumulated Expenses at $23.9 million in Q1 2026, $14.0 million in Q4 2025, and $30.1 million in Q3 2025.